Tbio | Unconventional myosin-X |
Isoform Headless: Functions as a dominant-negative regulator of isoform 1, suppressing its filopodia-inducing and axon outgrowth-promoting activities. In hippocampal neurons, it increases VASP retention in spine heads to induce spine formation and spine head expansion (By similarity).
This gene encodes a member of the myosin superfamily. The protein represents an unconventional myosin; it should not be confused with the conventional non-muscle myosin-10 (MYH10). Unconventional myosins contain the basic domains of conventional myosins and are further distinguished from class members by their tail domains. This gene functions as an actin-based molecular motor and plays a role in integration of F-actin and microtubule cytoskeletons during meiosis. [provided by RefSeq, Dec 2011]
This gene encodes a member of the myosin superfamily. The protein represents an unconventional myosin; it should not be confused with the conventional non-muscle myosin-10 (MYH10). Unconventional myosins contain the basic domains of conventional myosins and are further distinguished from class members by their tail domains. This gene functions as an actin-based molecular motor and plays a role in integration of F-actin and microtubule cytoskeletons during meiosis. [provided by RefSeq, Dec 2011]
Comments
Disease | Target Count | Z-score | Confidence |
---|---|---|---|
Weight Gain | 100 | 0.0 | 0.0 |
Disease | Target Count | P-value |
---|---|---|
malignant mesothelioma | 3232 | 1.4e-07 |
Atopic dermatitis | 952 | 2.2e-05 |
cystic fibrosis | 1696 | 2.2e-04 |
intraductal papillary-mucinous adenoma (IPMA) | 2955 | 3.5e-04 |
pituitary cancer | 1972 | 5.5e-04 |
intraductal papillary-mucinous carcinoma (IPMC) | 2989 | 7.1e-04 |
lung cancer | 4740 | 7.6e-04 |
psoriasis | 6694 | 1.2e-03 |
acute quadriplegic myopathy | 1158 | 1.3e-03 |
Down syndrome | 499 | 2.0e-03 |
ulcerative colitis | 1819 | 2.1e-03 |
ovarian cancer | 8520 | 3.5e-03 |
group 3 medulloblastoma | 4104 | 4.6e-03 |
intraductal papillary-mucinous neoplasm (IPMN) | 3291 | 4.8e-03 |
ductal carcinoma in situ | 1745 | 1.0e-02 |
oligodendroglioma | 2850 | 1.4e-02 |
colon cancer | 1478 | 3.6e-02 |
osteosarcoma | 7950 | 4.7e-02 |
Disease | Target Count | Z-score | Confidence |
---|---|---|---|
Disease of anatomical entity | 32 | 0.0 | 3.0 |
Mental Depression | 333 | 0.0 | 3.0 |
Disease | log2 FC | p |
---|---|---|
acute quadriplegic myopathy | 1.018 | 1.3e-03 |
Atopic dermatitis | 1.400 | 2.2e-05 |
colon cancer | 1.100 | 3.6e-02 |
cystic fibrosis | 1.700 | 2.2e-04 |
Down syndrome | 1.400 | 2.0e-03 |
ductal carcinoma in situ | 1.100 | 1.0e-02 |
group 3 medulloblastoma | 1.200 | 4.6e-03 |
intraductal papillary-mucinous adenoma (... | 1.700 | 3.5e-04 |
intraductal papillary-mucinous carcinoma... | 2.100 | 7.1e-04 |
intraductal papillary-mucinous neoplasm ... | 1.900 | 4.8e-03 |
lung cancer | 1.500 | 7.6e-04 |
malignant mesothelioma | -1.800 | 1.4e-07 |
oligodendroglioma | 1.500 | 1.4e-02 |
osteosarcoma | 1.602 | 4.7e-02 |
ovarian cancer | 1.700 | 3.5e-03 |
pituitary cancer | -2.100 | 5.5e-04 |
psoriasis | -2.100 | 1.2e-03 |
ulcerative colitis | -1.100 | 2.1e-03 |
Species | Source | Disease |
---|---|---|
Inparanoid OMA EggNOG | ||
Inparanoid OMA EggNOG | ||
Inparanoid OMA EggNOG | ||
Inparanoid OMA EggNOG | ||
Inparanoid OMA EggNOG | ||
OMA EggNOG | ||
Inparanoid OMA | ||
Inparanoid OMA EggNOG | ||
Inparanoid OMA | ||
Inparanoid OMA EggNOG | ||
OMA EggNOG | ||
Inparanoid OMA EggNOG | ||
Inparanoid OMA EggNOG |
MDNFFTEGTRVWLRENGQHFPSTVNSCAEGIVVFRTDYGQVFTYKQSTITHQKVTAMHPTNEEGVDDMAS 1 - 70 LTELHGGSIMYNLFQRYKRNQIYTYIGSILASVNPYQPIAGLYEPATMEQYSRRHLGELPPHIFAIANEC 71 - 140 YRCLWKRHDNQCILISGESGAGKTESTKLILKFLSVISQQSLELSLKEKTSCVERAILESSPIMEAFGNA 141 - 210 KTVYNNNSSRFGKFVQLNICQKGNIQGGRIVDYLLEKNRVVRQNPGERNYHIFYALLAGLEHEEREEFYL 211 - 280 STPENYHYLNQSGCVEDKTISDQESFREVITAMDVMQFSKEEVREVSRLLAGILHLGNIEFITAGGAQVS 281 - 350 FKTALGRSAELLGLDPTQLTDALTQRSMFLRGEEILTPLNVQQAVDSRDSLAMALYACCFEWVIKKINSR 351 - 420 IKGNEDFKSIGILDIFGFENFEVNHFEQFNINYANEKLQEYFNKHIFSLEQLEYSREGLVWEDIDWIDNG 421 - 490 ECLDLIEKKLGLLALINEESHFPQATDSTLLEKLHSQHANNHFYVKPRVAVNNFGVKHYAGEVQYDVRGI 491 - 560 LEKNRDTFRDDLLNLLRESRFDFIYDLFEHVSSRNNQDTLKCGSKHRRPTVSSQFKDSLHSLMATLSSSN 561 - 630 PFFVRCIKPNMQKMPDQFDQAVVLNQLRYSGMLETVRIRKAGYAVRRPFQDFYKRYKVLMRNLALPEDVR 631 - 700 GKCTSLLQLYDASNSEWQLGKTKVFLRESLEQKLEKRREEEVSHAAMVIRAHVLGFLARKQYRKVLYCVV 701 - 770 IIQKNYRAFLLRRRFLHLKKAAIVFQKQLRGQIARRVYRQLLAEKREQEEKKKQEEEEKKKREEEERERE 771 - 840 RERREAELRAQQEEETRKQQELEALQKSQKEAELTRELEKQKENKQVEEILRLEKEIEDLQRMKEQQELS 841 - 910 LTEASLQKLQERRDQELRRLEEEACRAAQEFLESLNFDEIDECVRNIERSLSVGSEFSSELAESACEEKP 911 - 980 NFNFSQPYPEEEVDEGFEADDDAFKDSPNPSEHGHSDQRTSGIRTSDDSSEEDPYMNDTVVPTSPSADST 981 - 1050 VLLAPSVQDSGSLHNSSSGESTYCMPQNAGDLPSPDGDYDYDQDDYEDGAITSGSSVTFSNSYGSQWSPD 1051 - 1120 YRCSVGTYNSSGAYRFSSEGAQSSFEDSEEDFDSRFDTDDELSYRRDSVYSCVTLPYFHSFLYMKGGLMN 1121 - 1190 SWKRRWCVLKDETFLWFRSKQEALKQGWLHKKGGGSSTLSRRNWKKRWFVLRQSKLMYFENDSEEKLKGT 1191 - 1260 VEVRTAKEIIDNTTKENGIDIIMADRTFHLIAESPEDASQWFSVLSQVHASTDQEIQEMHDEQANPQNAV 1261 - 1330 GTLDVGLIDSVCASDSPDRPNSFVIITANRVLHCNADTPEEMHHWITLLQRSKGDTRVEGQEFIVRGWLH 1331 - 1400 KEVKNSPKMSSLKLKKRWFVLTHNSLDYYKSSEKNALKLGTLVLNSLCSVVPPDEKIFKETGYWNVTVYG 1401 - 1470 RKHCYRLYTKLLNEATRWSSAIQNVTDTKAPIDTPTQQLIQDIKENCLNSDVVEQIYKRNPILRYTHHPL 1471 - 1540 HSPLLPLPYGDINLNLLKDKGYTTLQDEAIKIFNSLQQLESMSDPIPIIQGILQTGHDLRPLRDELYCQL 1541 - 1610 IKQTNKVPHPGSVGNLYSWQILTCLSCTFLPSRGILKYLKFHLKRIREQFPGSEMEKYALFTYESLKKTK 1611 - 1680 CREFVPSRDEIEALIHRQEMTSTVYCHGGGSCKITINSHTTAGEVVEKLIRGLAMEDSRNMFALFEYNGH 1681 - 1750 VDKAIESRTVVADVLAKFEKLAATSEVGDLPWKFYFKLYCFLDTDNVPKDSVEFAFMFEQAHEAVIHGHH 1751 - 1820 PAPEENLQVLAALRLQYLQGDYTLHAAIPPLEEVYSLQRLKARISQSTKTFTPCERLEKRRTSFLEGTLR 1821 - 1890 RSFRTGSVVRQKVEEEQMLDMWIKEEVSSARASIIDKWRKFQGMNQEQAMAKYMALIKEWPGYGSTLFDV 1891 - 1960 ECKEGGFPQELWLGVSADAVSVYKRGEGRPLEVFQYEHILSFGAPLANTYKIVVDERELLFETSEVVDVA 1961 - 2030 KLMKAYISMIVKKRYSTTRSASSQGSSR 2031 - 2058 //